Compounded semaglutide became widespread while FDA listed semaglutide injection products as in shortage. That listing was the legal basis for most of the compounding, and FDA declared the shortage over in February 2025. Here is what happened next, from FDA documents and court records, checked on November 17, 2026.
Quick answer: Compounded semaglutide is a prescription drug made by a licensed pharmacy or an FDA-registered outsourcing facility. It is not FDA-approved. Now that the shortage is over, 503A pharmacies may not make copies of the approved product regularly or in inordinate amounts, and 503B facilities may not compound it from bulk semaglutide. Research-grade semaglutide is a separate thing: a laboratory reagent for laboratory research use only, not for human or veterinary use.
What is compounded semaglutide?
Compounding means a pharmacist, physician or outsourcing facility prepares a drug outside an approved application. FDA's summary is direct: "Compounded drugs are not FDA-approved." That means FDA does not verify their safety, effectiveness or quality before they are marketed (FDA, Compounding Q&A).
Two sections of the Federal Food, Drug, and Cosmetic Act cover compounders:
- Section 503A covers state-licensed pharmacies and physicians, who compound for an individual patient based on a prescription.
- Section 503B covers outsourcing facilities, created in 2013, which register with FDA and must meet current good manufacturing practice (CGMP) requirements.
The FDA-approved semaglutide products are Novo Nordisk's Ozempic, Rybelsus and Wegovy. FDA's March 2026 announcement adds that compounded drugs "are also not the same as generic drugs, which are FDA-approved" (FDA, March 3, 2026). For background on how the two pathways work, see our guide to 503A compounding and FDA's bulk substance categories.
Why could pharmacies compound semaglutide during the shortage?
Federal law limits how closely a compounded drug may copy an approved one, and some of those limits relax while a drug is on FDA's shortage list. FDA's order names them: the 503A limit on drugs that are "essentially a copy" of a commercially available product, and the 503B limits on compounding from bulk and on copying an approved drug.
According to the same order, semaglutide injection products were first added to the shortage list in March 2022 for Wegovy and in August 2022 for Ozempic (FDA declaratory order, February 21, 2025). While they stayed listed, those limits did not block compounding.
When did the semaglutide shortage end?
On February 21, 2025, FDA issued a declaratory order finding the shortage resolved. FDA said data from Novo Nordisk showed its supply was "currently meeting or exceeding demand," with reserves of finished and semi-finished product. FDA said information from compounders, telehealth companies and individuals had "important limitations."
FDA added that people may still see intermittent, localized supply disruptions after a shortage is resolved. Under the statute, that is not a national shortage.
Semaglutide shortage and compounding timeline
| Date | What happened |
|---|---|
| March 2022 | Semaglutide injection (Wegovy) added to FDA's shortage list |
| August 2022 | Semaglutide injection (Ozempic) added to the list |
| February 21, 2025 | FDA declares the shortage resolved |
| April 24, 2025 | Court denies compounders' request for a preliminary injunction; FDA says the 503A grace period has ended |
| May 22, 2025 | 503B grace period ends |
| February 6, 2026 | FDA says it intends to restrict GLP-1 active ingredients used in non-approved compounded drugs |
| April 30, 2026 | FDA proposes keeping semaglutide off the 503B bulks list |
| August 27, 2026 | Fifth Circuit affirms the judgment for FDA |
| November 17, 2026 | FDA database still lists the shortage as resolved |
What may 503A pharmacies and 503B facilities do now?
The February 2025 order gave 503A pharmacies until April 22, 2025 and 503B outsourcing facilities until May 22, 2025 to wind down. After a court denied a preliminary injunction on April 24, 2025, FDA said the 503A period had ended (FDA compounding policy page).
FDA restated the standing rules on April 1, 2026:
- 503A pharmacies must compound for an individual patient based on a prescription. They may not compound essentially copies of a commercially available drug "regularly or in inordinate amounts," unless the prescriber documents a significant difference for that patient. FDA said it does not intend to act against a compounder that fills four or fewer prescriptions of such a product in a calendar month.
- 503B outsourcing facilities generally may compound from a bulk drug substance only if it is on the 503B bulks list or the drug is on FDA's shortage list. FDA stated that semaglutide is on neither.
FDA has since moved to settle the 503B question. On April 30, 2026, it proposed not to add semaglutide, tirzepatide or liraglutide to the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk (FDA, April 30, 2026). The Federal Register notice ran on May 1, 2026, and FDA extended the comment period to July 30, 2026. When we checked on November 17, 2026, we found no final determination.
What has FDA warned about compounded semaglutide?
Salt forms
FDA says some compounders have sold products made with salt forms of semaglutide, "including semaglutide sodium and semaglutide acetate." FDA calls these different active ingredients from the one in the approved drugs, and says it is not aware of any lawful basis for using them in compounding (FDA's concerns with unapproved GLP-1 drugs).
Dosing errors
In July 2024, FDA warned of adverse events linked to dosing errors with compounded semaglutide injections (FDA alert). FDA described errors made when patients measured their own doses from multiple-dose vials and when clinicians miscalculated doses. Some patients sought medical care or were hospitalized. FDA has also received reports involving doses beyond the FDA-approved label.
As of May 31, 2026, FDA said it had received 990 reports of adverse events associated with compounded semaglutide. FDA notes that adverse events with compounded drugs are likely underreported.
Sourcing, imports and marketing
- September 5, 2025: FDA set up a "green list" import alert. GLP-1 active ingredients from facilities FDA has not inspected or evaluated can be detained at the border (FDA).
- February 6, 2026: FDA said it intends to restrict GLP-1 active ingredients used in non-FDA-approved compounded drugs sold by mass marketers. It said companies may not claim their compounded products are generic, the same as approved drugs, or clinically proven, and warned of seizure and injunction (FDA).
- March 3, 2026: FDA sent 30 warning letters to telehealth companies over claims implying sameness with approved products.
- October 30, 2026: FDA sent a warning letter to RonanRx, Inc. dba RonanRx, a telehealth company (FDA). FDA said it reviewed the company's website and social media in September 2026 and that the website offered compounded semaglutide and tirzepatide products. The letter states that claims there were false or misleading under sections 502(a) and 502(bb) of the Act. FDA grouped them three ways: labeling that suggested the company itself compounded the products, claims that implied FDA approval or evaluation, and claims about where the products were made. A warning letter states FDA's view. It is not a court finding.
- U.S. Food and Drug Administration. (2026, October 30). Warning letter: RonanRx, Inc. dba RonanRx, MARCS-CMS 737905. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ronanrx-inc-dba-ronanrx-737905-10302026
What did the courts decide?
The Outsourcing Facilities Association and a compounding pharmacy sued FDA over the delisting in the Northern District of Texas (No. 4:25-cv-174). The district court denied a preliminary injunction on April 24, 2025. It later entered summary judgment for FDA and for Novo Nordisk, which had joined the case.
On August 27, 2026, the Fifth Circuit affirmed (No. 25-10758). The panel held that any notice-and-comment error was harmless and that FDA's decision was not arbitrary or capricious. A parallel tirzepatide appeal was decided the same day; see our compounded tirzepatide guide.
What is the status of compounded semaglutide today?
This is what the public record showed on November 17, 2026:
- Shortage: FDA's drug shortage database lists semaglutide injection as "Resolved" (FDA database). FDA's shortage data separately lists certain oral semaglutide tablet presentations as "to be discontinued," posted June 4, 2026 (openFDA). That is a discontinuation notice, not a shortage of the injection.
- 503A: The grace period is over; regular copies are not allowed.
- 503B: Semaglutide is not on the 503B bulks list, and FDA has proposed keeping it off.
- Courts: The appeal was decided in FDA's favor.
Shortage status can change, so check FDA's database for the current listing.
How is research-grade semaglutide different?
Research-grade semaglutide is a laboratory reagent, sold for laboratory research use only, not for human or veterinary use. It is not compounded for a patient, not dispensed on a prescription and not FDA-approved. It is not an alternative to a prescription medicine.
FDA has drawn this line in its enforcement. It has warned companies that sold unapproved semaglutide and tirzepatide products "falsely labeled" for research purposes or "not for human consumption," noting that "these products have been sold directly to consumers for human use with dosing instructions." In a February 2025 warning letter, FDA said that despite "research use only" statements, evidence from a seller's website showed its semaglutide and tirzepatide products were drugs intended for human use. Under FDA's regulations, intended use is judged by objective evidence, including labeling claims, advertising and the circumstances of sale (21 CFR 201.128).
See what research use only means for more. If you are looking for semaglutide as a treatment, the route is a licensed prescriber and a licensed pharmacy. Our page on semaglutide and tirzepatide prescription labels links each FDA label.
Frequently asked questions about compounded semaglutide
Is compounded semaglutide legal?
Compounding is legal when a pharmacy or outsourcing facility meets the conditions of section 503A or 503B, and since the shortage ended those conditions sharply limit it. 503A pharmacies may not make copies of the approved product regularly or in inordinate amounts, 503B facilities may not compound it from bulk, and FDA says salt forms have no lawful basis.
Is semaglutide still in shortage?
No. FDA declared the shortage resolved on February 21, 2025, and its database listed semaglutide injection as resolved when we checked on November 17, 2026.
Did a court overturn FDA's decision?
No. The district court ruled for FDA, and the Fifth Circuit affirmed on August 27, 2026.
Is research-grade semaglutide the same as compounded semaglutide?
No. Compounded semaglutide is a prescription drug prepared for a patient. Research-grade semaglutide is a laboratory reagent, not for human or veterinary use.
What to know now
- Shortage: resolved February 21, 2025; still resolved on November 17, 2026.
- Grace periods: ended April 2025 for 503A and May 22, 2025 for 503B.
- Rules now: no regular 503A copies; no 503B compounding from bulk semaglutide.
- FDA warnings: salt forms, dosing errors and misleading marketing.
- Courts: FDA upheld; Fifth Circuit affirmed August 27, 2026.
- Research grade: a laboratory reagent, not for human or veterinary use.
What we're watching
FDA's final decision on the 503B bulks list proposal, how FDA carries out its February 2026 restriction on GLP-1 active ingredients, and any change to the shortage listing.